Mostrar el registro sencillo del ítem

dc.contributor.authorMatiello, Julianapt_BR
dc.contributor.authorDal Prá, Alan L.pt_BR
dc.contributor.authorZardo, Laisept_BR
dc.contributor.authorSilva, Ricardopt_BR
dc.contributor.authorBerton, Danilo Cortozipt_BR
dc.date.accessioned2021-08-31T04:20:48Zpt_BR
dc.date.issued2020pt_BR
dc.identifier.issn1759-7706pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/226313pt_BR
dc.description.abstractBackground: We evaluated the impact of thoracic radiation in patients withnon-small cell lung cancer (NSCLC), considering the depletion of total lympho-cytes, use or not of chemotherapy, and radiation doses in healthy lung tissue.Methods: Patients with stage III NSCLC, ECOG 0 to 2, receiving radiothera pywith or without chemotherapy were prospectively evaluated. All patients shouldbe treated with three-dimensional radiotherapy and received biologically effectivedoses (BED10α/β 10) of 48 to 80 Gy. Peripheral blood lymphocyte total countswere measured at the start of radiotherapy and at 2, 6 and 12 months after radio-therapy. Along with lymphocytes, PTV and doses of 5 Gy and 20 Gy in healthylung tissue were also evaluated as potential factors inuencing overall survival(OS) and progression-free survival (PFS).Results: A total of 46 patients were prospectively evaluated from April 2016 toAugust 2019, with a median follow-up of 13 months (interquartile range, 1–39months). The median of OS of all cohort was 22,8 months (IC 95% 17,6–28,1)and the median PFS was 19,5 months (IC 95%: 14,7–24,2). Most patientsreceived concurrent or neoadjuvant chemotherapy (43; 93.4%). No patientreceived adjuvant immunotherapy. The lower the lymphocyte loss at 6 monthsafter radiotherapy (every 100 lymphocytes/mcL), the greater the chance of PFS(HR, 0.44; 95%CI, 0.25–0.77; P = 0.004) and OS (HR, 0.83; 95%CI, 0.70–0.98;P = 0.025; P = 0.025). BED was a protective factor for both PFS (HR, 0.52; 95%CI 0.33 –0.83; P = 0.0006) and OS (HR, 0.73; 95%CI 0.54–0.97; P = 0.029).Conclusions: Our results suggest that lymphocyte depletion after radiotherapyreduces tumor control and survival in patients with stage III lung cancer. Radia-tion doses equal or higher than 60 Gy (BED1072 Gy) improve PFS and OS, butthey negatively affect lymphocyte counts for months, which reduces survival andthe potential of immunotherapy.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofThoracic cancer. Singapore. Vol. 11 (2020), p. 3139–3144.pt_BR
dc.rightsOpen Accessen
dc.subjectLymphocyte counten
dc.subjectContagem de linfócitospt_BR
dc.subjectNon-small cell lung canceren
dc.subjectNeoplasias pulmonarespt_BR
dc.subjectIntervalo livre de progressãopt_BR
dc.subjectProgression-free survivalen
dc.subjectSobrevidapt_BR
dc.subjectSurvivalen
dc.subjectRadioterapiapt_BR
dc.subjectThoracic irradiationen
dc.titleImpacts of post-radiotherapy lymphocyte count onprogression-free and overall survival in patients with stage III lung cancerpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001129830pt_BR
dc.type.originEstrangeiropt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem